|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ang C, O'Reilly EM and Abou-Alfa GK:
Targeted agents and systemic therapy in hepatocellular carcinoma.
Recent Results Cancer Res. 190:225–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chirikov VV, Mullins CD, Hanna N, Breunig
IM, Seal B and Shaya FT: Multispecialist care and mortality in
hepatocellular carcinoma. Am J Clin Oncol. 38:557–563. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gomes MA, Priolli DG, Tralhão JG and
Botelho MF: Hepatocellular carcinoma: Epidemiology, biology,
diagnosis, and therapies. Rev Assoc Med Bras 1992. 59:514–524.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ranieri G, Marech I, Lorusso V, Goffredo
V, Paradiso A, Ribatti D and Gadaleta CD: Molecular targeting
agents associated with transarterial chemoembolization or
radiofrequency ablation in hepatocarcinoma treatment. World J
Gastroenterol. 20:486–497. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tampaki M, Doumba PP, Deutsch M and
Koskinas J: Circulating biomarkers of hepatocellular carcinoma
response after locoregional treatments: New insights. World J
Hepatol. 7:1834–1842. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu
M, Ghilardi M, Lonati V and Barni S: Oxaliplatin-based
chemotherapy: A new option in advanced hepatocellular carcinoma. A
systematic review and pooled analysis. Clin Oncol (R Coll Radiol).
26:488–496. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdel-Rahman O: Revisiting
oxaliplatin-based regimens for advanced hepatocellular carcinoma.
Curr Oncol Rep. 16:3942014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong L, Han Y, Zhou Y and Nita A:
Angiogenesis-related microRNAs in colon cancer. Expert Opin Biol
Ther. 13:77–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu CH, Kang YK, Yang TS, Shun CT, Shao
YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, et al:
Bevacizumab with erlotinib as first-line therapy in Asian patients
with advanced hepatocellular carcinoma: A multicenter phase II
study. Oncology. 85:44–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takayasu K: Chemoembolization for
unresectable hepatocellular carcinoma in Japan. Oncology. 78 (Suppl
1):135–141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khan JA, Maki RG and Ravi V: Pathologic
angiogenesis of malignant vascular sarcomas: Implications for
treatment. J Clin Oncol. 36:194–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang CH, Pfeffer SR, Sims M, Yue J, Wang
Y, Linga VG, Paulus E, Davidoff AM and Pfeffer LM: The oncogenic
microRNA-21 inhibits the tumor suppressive activity of FBXO11 to
promote tumorigenesis. J Biol Chem. 290:6037–6046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yodono H, Matsuo K and Shinohara A: A
retrospective comparative study of epirubicin-lipiodol emulsion and
cisplatin-lipiodol suspension for use with transcatheter arterial
chemoembolization for treatment of hepatocellular carcinoma.
Anticancer Drugs. 22:277–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang-Yuan Z, Jiang-Zheng Z, Lu YD, Hao XB,
Hong T, Huang F, Lei JH, He ZH and Huang MZ: Clinical efficacy of
metronomic chemotherapy after cool-tip radiofrequency ablation in
the treatment of hepatocellular carcinoma. Int J Hyperthermia.
32:193–198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marinelli S, Granito A, Piscaglia F,
Renzulli M, Stagni A and Bolondi L: Metronomic capecitabine in
patients with hepatocellular carcinoma unresponsive to or
ineligible for sorafenib treatment: Report of two cases. Hepat Mon.
13:e117212013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He SL, Shen J, Sun XJ, Zhu XJ, Liu LM and
Dong JC: Efficacy of capecitabine and oxaliplatin regimen for
extrahepatic metastasis of hepatocellular carcinoma following local
treatments. World J Gastroenterol. 19:4552–4558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maj E, Papiernik D and Wietrzyk J:
Antiangiogenic cancer treatment: The great discovery and greater
complexity. Int J Oncol. 49:1773–1784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y,
Zhang Z, Zheng L, Deng H, Li S, et al: Hepatic arterial infusion of
oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced
hepatocellular carcinoma. J Hepatol. 69:60–69. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin F, Ji H, Jia C, Brockmeier U, Hermann
DM, Metzen E, Zhu Y and Chi B: Synergistic antitumor effects of
endostar in combination with oxaliplatin via inhibition of HIF and
CXCR4 in the colorectal cell line SW1116. PLoS One. 7:1–9. 2012.
View Article : Google Scholar
|
|
21
|
Beringer DX, Kleijwegt FS, Wiede F, van
der Slik AR, Loh KL, Petersen J, Dudek NL, Duinkerken G, Laban S,
Joosten A, et al: T cell receptor reversed polarity recognition of
a self-antigen major histocompatibility complex. Nat Immunol.
16:1153–1161. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou J, Yang T, Liu L and Lu B:
Chemotherapy oxaliplatin sensitizes prostate cancer to immune
checkpoint blockade therapies via stimulating tumor immunogenicity.
Mol Med Rep. 16:2868–2874. 2017. View Article : Google Scholar : PubMed/NCBI
|
